These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33751832)

  • 21. The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.
    Kim SH; Cho BC; Choi HJ; Chung KY; Kim DJ; Park MS; Kim SK; Chang J; Shin SJ; Sohn JH; Kim JH
    Lung Cancer; 2008 Jun; 60(3):393-400. PubMed ID: 18155802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survivin mRNA Level in Blood Predict the Efficacy of Neoadjuvant Chemotherapy in Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hu YM; Li J; Yu LC; Shi SB; Du YJ; Wu JN; Shi WL
    Pathol Oncol Res; 2015 Apr; 21(2):257-65. PubMed ID: 24980156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant therapy following induction therapy and surgery improves survival in N2-positive non-small cell lung cancer.
    White AA; Lee DN; Mazzola E; Kucukak S; Polhemus E; Jaklitsch MT; Mentzer SJ; Wee JO; Bueno R; Swanson SJ
    J Surg Oncol; 2021 Feb; 123(2):579-586. PubMed ID: 33259637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).
    Wislez M; Mazieres J; Lavole A; Zalcman G; Carre O; Egenod T; Caliandro R; Dubos-Arvis C; Jeannin G; Molinier O; Massiani MA; Langlais A; Morin F; Le Pimpec Barthes F; Brouchet L; Assouad J; Milleron B; Damotte D; Antoine M; Westeel V
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36270733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy.
    Corsini EM; Weissferdt A; Pataer A; Zhou N; Antonoff MB; Hofstetter WL; Mehran RJ; Rajaram R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Cascone T; Heymach JV; Swisher SG; Sepesi B
    Eur J Cardiothorac Surg; 2021 Jan; 59(1):100-108. PubMed ID: 32864702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of treatment interval between neoadjuvant immunochemotherapy and surgery in lung squamous cell carcinoma.
    Gu C; Teng X; Sun X; Liu J; Zhu Z; Zhang L; Wu Z; Zou R; Pang J; Lyu X
    BMC Cancer; 2024 May; 24(1):585. PubMed ID: 38741038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune-related histologic phenotype in pretreatment tumour biopsy predicts the efficacy of neoadjuvant anti-PD-1 treatment in squamous lung cancer.
    Yuan P; Guo C; Li L; Ling Y; Guo L; Ying J
    BMC Med; 2022 Oct; 20(1):403. PubMed ID: 36280845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes.
    Haque W; Verma V; Butler EB; Teh BS
    Lung Cancer; 2019 Apr; 130():93-100. PubMed ID: 30885358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study.
    Dai F; Wu X; Wang X; Li K; Wang Y; Shen C; Zhou J; Niu H; Deng B; Tan Q; Wang R; Guo W
    Front Oncol; 2022; 12():1022123. PubMed ID: 36353552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A real-world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non-small cell lung cancer.
    Zhang B; Xiao H; Pu X; Zhou C; Yang D; Li X; Wang W; Xiao Q
    Cancer Med; 2023 Jan; 12(1):274-286. PubMed ID: 35621048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymph-node ratio predicts survival among the different stages of non-small-cell lung cancer: a multicentre analysis†.
    Chiappetta M; Leuzzi G; Sperduti I; Bria E; Mucilli F; Lococo F; Spaggiari L; Ratto GB; Filosso PL; Facciolo F
    Eur J Cardiothorac Surg; 2019 Mar; 55(3):405-412. PubMed ID: 30202953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of EGFR driver mutations on pathologic regression in resectable locally advanced non-small cell lung cancer treated with neoadjuvant chemoradiation and completion surgery.
    Appel S; Bar J; Saad A; Marom EM; Urban D; Onn A; Gantz-Sorotsky H; Kremer RY; Ben-Nun A; Perelman M; Ofek E; Yacobi R; Daher S; Rasco A; Symon Z; Lawrence YR; Goldstein J
    Br J Radiol; 2023 Dec; 96(1152):20220763. PubMed ID: 37751214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer.
    Li J; Shi SB; Shi WL; Wang Y; Yu LC; Zhu LR; Ge LP
    Transl Res; 2014 Jan; 163(1):27-35. PubMed ID: 24120632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
    Shinde A; Horne ZD; Li R; Glaser S; Massarelli E; Koczywas M; Erhunmwunsee L; Reckamp KL; Weksler B; Salgia R; Beriwal S; Amini A
    Lung Cancer; 2019 Jul; 133():136-143. PubMed ID: 31200820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors.
    Sun X; Feng Y; Zhang B; Huang W; Zhao X; Zhang H; Yue D; Wang C
    Cancer Res Treat; 2022 Oct; 54(4):1017-1029. PubMed ID: 34809413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis.
    Chen Y; Qin J; Wu Y; Lin Q; Wang J; Zhang W; Liang F; Hui Z; Zhao M; Wang J
    Int J Surg; 2023 Sep; 109(9):2794-2807. PubMed ID: 37247009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy.
    Liu Z; Gao Z; Zhang M; Wang X; Gong J; Jiang S; Zhang Z
    Ann Thorac Cardiovasc Surg; 2022 Apr; 28(2):111-120. PubMed ID: 34776459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
    Mouillet G; Monnet E; Milleron B; Puyraveau M; Quoix E; David P; Ducoloné A; Molinier O; Zalcman G; Depierre A; Westeel V;
    J Thorac Oncol; 2012 May; 7(5):841-9. PubMed ID: 22722786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
    Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
    J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.